The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.

NEW YORK – Osteoporosis diagnostic firm Osteolabs announced Wednesday that it has entered into a strategic partnership with Swiss medical laboratory Labor Team to distribute Osteolabs' test for ...

The work will focus on addressing unmet needs in breast cancer, including the diagnosis and treatment of patients with rare cancer subtypes.

The protein biomarker-based test will be used to identify patients at high risk of cancer in order to prioritize them for conventional cancer screening methods.

Last week, readers were most interested in a story about the FDA's decision not to appeal a court decision vacating the agency's LDT rule.

The test is the last of three multiplex bloodstream infection panels that the firm has designed for its Liaison Plex molecular testing instrument.

NEW YORK – Randox Laboratories said this week that it has secured US Food and Drug Administration de novo marketing authorization for a companion diagnostic immunoassay to help determine the ...

The three-year award from the National Institute for Health and Care Research will support finalization of the test as well as initial validation studies.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

NEW YORK – Danaher subsidiary Cepheid announced Wednesday that its Xpert HIV-1 Viral Load XC assay has received a medical device license from Health Canada. The next-generation extended coverage test ...

NEW YORK — Chicago-based academic health system Northwestern Medicine has struck a deal to collaborate with PathAI on its cloud-based AISight digital pathology image management system, the partners ...

Called Velo, the system can perform true PCR testing in 10 minutes or less and is intended for use in decentralized spaces.